Comparison Overview
SPRAVATO® (esketamine) for HCPs
SPRAVATO® (esketamine) for HCPs
N/A
Last Update: 19/02/2026
Please read full Important Safety Information below in the pinned post and at www.spravatohcp.com/PI/. This product is intended for US Healthcare Professionals only. SPRAVATO® is a product of Johnson & Johnson and is not associated with any individual users on LinkedI...
AUROBINDO PHARMA LTD
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, 500032, IN
Last Update: 03/04/2026
Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, brand...
Compliance Ranges Comparison
SPRAVATO® (esketamine) for HCPs
AUROBINDO PHARMA LTD
Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for SPRAVATO® (esketamine) for HCPs in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for AUROBINDO PHARMA LTD in 2026.
Incident History - SPRAVATO® (esketamine) for HCPs (X = Date, Y = Severity)
SPRAVATO® (esketamine) for HCPs cyber incidents detection timeline including parent company and subsidiaries.
Incident History - AUROBINDO PHARMA LTD (X = Date, Y = Severity)
AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents
SPRAVATO® (esketamine) for HCPs
AUROBINDO PHARMA LTD
FAQ
Latest Global CVEs
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.
Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.